Search alternatives:
non decrease » point decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
Showing 13,061 - 13,080 results of 39,200 for search '(( 50 ((mean decrease) OR (a decrease)) ) OR ( 5 ((non decrease) OR (nn decrease)) ))', query time: 1.09s Refine Results
  1. 13061
    Cyclic fatigue test block.

    Cyclic fatigue test block. by Beliz Özel (16475132)

    Published 2024
    Save to List
    Saved in:
  2. 13062
    rNMP incorporation frequency of Pol γ and the mtDNA replisome on long DNA templates.

    rNMP incorporation frequency of Pol γ and the mtDNA replisome on long DNA templates. by Josefin M. E. Forslund (5043218)

    Published 2018
    Save to List
    Saved in:
  3. 13063
    GFP localization and expression in wild-type and <i>tbc-2</i> mutants.

    GFP localization and expression in wild-type and <i>tbc-2</i> mutants. by İçten Meraş (13184380)

    Published 2022
    Save to List
    Saved in:
  4. 13064
    The aging parameters of each group of batteries.

    The aging parameters of each group of batteries. by Peijian Jin (22265437)

    Published 2025
    “…All battery groups produced pulse-type acoustic emission signals during the charging and discharging processes at 1C and 0.5C. The acoustic emission waveforms exhibited a dual-peak characteristic throughout the entire charging and discharging cycles. …”
    Save to List
    Saved in:
  5. 13065
    Minimal data set.

    Minimal data set. by Peijian Jin (22265437)

    Published 2025
    “…All battery groups produced pulse-type acoustic emission signals during the charging and discharging processes at 1C and 0.5C. The acoustic emission waveforms exhibited a dual-peak characteristic throughout the entire charging and discharging cycles. …”
    Save to List
    Saved in:
  6. 13066
    Experimental lithium-ion batteries.

    Experimental lithium-ion batteries. by Peijian Jin (22265437)

    Published 2025
    “…All battery groups produced pulse-type acoustic emission signals during the charging and discharging processes at 1C and 0.5C. The acoustic emission waveforms exhibited a dual-peak characteristic throughout the entire charging and discharging cycles. …”
    Save to List
    Saved in:
  7. 13067
    Schematic diagram of two time intervals.

    Schematic diagram of two time intervals. by Peijian Jin (22265437)

    Published 2025
    “…All battery groups produced pulse-type acoustic emission signals during the charging and discharging processes at 1C and 0.5C. The acoustic emission waveforms exhibited a dual-peak characteristic throughout the entire charging and discharging cycles. …”
    Save to List
    Saved in:
  8. 13068
    Binding of nucleotide and compound 1 to yeast F<sub>1</sub> α- and β-subunits.

    Binding of nucleotide and compound 1 to yeast F<sub>1</sub> α- and β-subunits. by Lindsay B. Tulloch (1266861)

    Published 2017
    Save to List
    Saved in:
  9. 13069
    B-THP-Ts bind to C-terminal GFP-PTP tagged F<sub>1</sub> α- and β- subunits.

    B-THP-Ts bind to C-terminal GFP-PTP tagged F<sub>1</sub> α- and β- subunits. by Lindsay B. Tulloch (1266861)

    Published 2017
    Save to List
    Saved in:
  10. 13070
    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for Parkinson’s Disease

    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for... by Javier García-Cárceles (2073898)

    Published 2022
    Save to List
    Saved in:
  11. 13071
    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for Parkinson’s Disease

    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for... by Javier García-Cárceles (2073898)

    Published 2022
    Save to List
    Saved in:
  12. 13072
    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for Parkinson’s Disease

    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for... by Javier García-Cárceles (2073898)

    Published 2022
    Save to List
    Saved in:
  13. 13073
    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for Parkinson’s Disease

    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for... by Javier García-Cárceles (2073898)

    Published 2022
    Save to List
    Saved in:
  14. 13074
    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for Parkinson’s Disease

    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for... by Javier García-Cárceles (2073898)

    Published 2022
    Save to List
    Saved in:
  15. 13075
    Effects of compounds on mitochondrial membrane potential.

    Effects of compounds on mitochondrial membrane potential. by Lindsay B. Tulloch (1266861)

    Published 2017
    Save to List
    Saved in:
  16. 13076
    Inhibition of ATP production in digitonin-permeabilsed cells.

    Inhibition of ATP production in digitonin-permeabilsed cells. by Lindsay B. Tulloch (1266861)

    Published 2017
    Save to List
    Saved in:
  17. 13077
    Supplementary Material for: Off-label Use of Mycophenolate Mofetil in Immunoglobulin A Nephropathy: A Systematic Review and Meta-analysis

    Supplementary Material for: Off-label Use of Mycophenolate Mofetil in Immunoglobulin A Nephropathy: A Systematic Review and Meta-analysis by Feng L. (5056958)

    Published 2024
    “…Introduction: Mycophenolate mofetil (MMF) is widely used off-label in patients with immunoglobulin A nephropathy (IgAN), although the literature does not consistently agree on its efficacy and safety. …”
    Save to List
    Saved in:
  18. 13078
    DAF-16 FOXO localizes to vesicles in intestinal cells.

    DAF-16 FOXO localizes to vesicles in intestinal cells. by İçten Meraş (13184380)

    Published 2022
    Save to List
    Saved in:
  19. 13079
    Comparative GSIS of human Islets and cultured human islet cells from 6 donors as a function of PDLs.

    Comparative GSIS of human Islets and cultured human islet cells from 6 donors as a function of PDLs. by Anna M. Gooch (16877409)

    Published 2023
    Save to List
    Saved in:
  20. 13080
    Manager’s characteristics.

    Manager’s characteristics. by Martina Wallberg (16052714)

    Published 2023
    Save to List
    Saved in:

Search Tools: